News

Avella Newsroom

January 1, 1970|
The Value Proposition of Specialty Care
July 20, 2017| CATEGORIES: Specialty Pharmacy , Press Feature

Rebecca Shanahan, JD, the CEO of Avella Specialty Pharmacy, in Phoenix, suggested that the dramatic change in hepatitis C virus (HCV)—from a life-threatening disease to a curable one—illustrates well the evolution of specialty pharmacy.

Congress, Please Keep Your Medicare Promises to Our Seniors
May 4, 2017| CATEGORIES: Specialty Pharmacy , Press Mention

This opinion article featured in The Hill is authored by Rebecca Shanahan, CEO of Avella Specialty Pharmacy and President of the National Association of Specialty Pharmacy (NASP). 

Medicare was created in 1966 as a promise to protect our seniors. But the security of aging Americans is increasingly threatened.

Here’s how Medicare Part D is supposed to work: seniors go to the pharmacy of their choosing, exchange their co-pay for medications, and pay a monthly premium toward a Part D insurance plan that is administered by a pharmacy benefit manager (PBM). Unfortunately, big PBMs — the private insurers who sell Medicare Part D plans to seniors — are rigging the system by imposing unfair “direct and indirect remuneration fees,” or DIR fees.

Avella CEO Letter Regarding Direct and Indirect Remuneration (DIR) Fees
March 29, 2017| CATEGORIES: Specialty Pharmacy , Press Release

Calling on Centers for Medicare & Medicaid Services to Curb Below-Cost Reimbursement to Specialty Pharmacies by Pharmaceutical Benefit Managers, to Clarify Medicare Definitions, & Promote Accurate & Responsible Reimbursement

Direct & Indirect Remuneration (DIR) fees erode access to vital clinical services & breakthrough drugs for the most vulnerable Americans, increasing costs across the board & negatively impacting seniors & their caregivers, pharmacies, & taxpayers that fund Medicare

Last week, Frier Levitt, LLC; and the National Association of Specialty Pharmacy (NASP) published a white paper describing the advent and negative consequences of Direct and Indirect Remuneration (DIR) fees. America’s seniors need the Centers for Medicare and Medicaid Services (CMS) to take immediate action to stop Pharmaceutical Benefits Managers (PBMs) from levying inappropriate, unreasonable and unsustainable DIR fees on specialty pharmacies.

The Pharmaceutical Ecosystem Must Work Together to Provide Sustainable Innovation and Ensure Patient Access
March 15, 2017| CATEGORIES: Specialty Pharmacy , Press Mention

For many patients with rare diseases, reaching the first step of an accurate diagnosis can be a lengthy journey, riddled with pain, difficulty, and trial and error—and that’s before they begin the challenge of fighting and treating their conditions.

Once diagnosed, patients with rare diseases often face a new set of challenges: affordability, adherence to complex regimens, side effect management, and coordination of follow-up appointments that may involve providers far from home. And yet, innovative therapies are emerging that offer patients, including those who had previously exhausted all other options, new opportunities for improved health outcomes.

NASP President Discusses the Role of Specialty Pharmacy in the Health Care Ecosystem (Part 2)
February 22, 2017| CATEGORIES: Specialty Pharmacy , Press Mention
In a 2-part Q&A with Specialty Pharmacy Times, NASP President Rebecca Shanahan discussed how direct and indirect remuneration (DIR) fees affect specialty pharmacy, how to improve patient outcomes, the impact of Any Willing Provider legislation on payer access and patient services, and many other hot topics in the specialty landscape. Click here to read part 1 of the interview. 

SPT: What is the role of ACOs, GPOs, or individual institutions in specialty pharmacy?
NASP Discusses the Future of Specialty Pharmacy (Part 1)
February 21, 2017| CATEGORIES: Specialty Pharmacy , Press Mention
In a 2-part Q&A with Specialty Pharmacy Times, NASP President Rebecca Shanahan discussed how direct and indirect remuneration (DIR) fees affect specialty pharmacy, how to improve patient outcomes, the impact of Any Willing Provider legislation on payer access and patient services, and many other hot topics in the specialty landscape.

SPT: Compare the impact of DIR fees on specialty pharmacy and the differences in the specialty pharmacy model compared with traditional retail?
Specialty Pharmacies Transforming Cancer Care
February 21, 2017| CATEGORIES: Specialty Pharmacy , Oncology , Cancer , Press Mention
As the model of collaborative healthcare expands and grows, every person who participates in patient care will have a distinct role to play to improve patient outcomes. Specialty pharmacies are increasingly bearing the charge of dispensing, distribution reimbursement, case management, and other services that serve a patient’s specific disease needs.

From adherence management to communicating with physicians, coordinating financial assistance, and managing prior authorization, specialty pharmacies offer patients a variety of comprehensive services. At the Patient-Centered Oncology Care® meeting, held November 17-18, 2016, in Baltimore, J. Ike Nicoll, President, The Morrison Group, and Joshua A. Rademacher, MBA, executive vice president, Enterprise Solutions and Business Development, at Avella Specialty Pharmacy, spoke to pairing novel cancer treatments with high-touch and high-technology support. 
News Alerts
If you would like to receive email updates from Avella Specialty Pharmacy, please complete the information below.
Subscribe
Featured Video
Photo of Brian Halligan
Path of a Specialty Prescription
The path of a specialty prescription is complex. This video details each step of the path and the unique offerings of Avella.
News Alerts
If you would like to receive email updates from Avella Specialty Pharmacy, please complete the information below.
Subscribe